RxAll key facts
- Developer of a deep learning hyperspectral IoT platform designed for authenticating drugs in real-time.
- It has raised $5.8M; the latest was Accelerator/Incubator in Apr 2025.
- Notable investors include Plug and Play Tech Center, SOSV, Harvard Innovation Launch Lab, HAX, Launch Africa Ventures — 24 tracked in total.
- Status: Privately Held (backing).
Who backs RxAll
24+- ·The complete investor list: 24 names
- ·Watch RxAll: the Monday email on marks, rounds and moves
RxAll funding rounds
No funding rounds for RxAll are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
RxAll investors
24 investors are on record for RxAll, including Plug and Play Tech Center, SOSV, Harvard Innovation Launch Lab and HAX.
About RxAll
Developer of a deep learning hyperspectral IoT platform designed for authenticating drugs in real-time. The company's platform works through spectrometers and a cloud data set of spectral signatures of medicines to carry out non-destructive product authentication, enabling pharma manufacturers to get information in real-time about counterfeiting of their products and making high-quality medicines accessible to everyone at affordable prices.
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2016
- Employees
- 24
- Website
- rxall.net/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
RxAll doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.